Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply
N Engl J Med
.
2022 May 5;386(18):1768.
doi: 10.1056/NEJMc2202778.
Authors
Steven R Ytterberg
1
,
Deepak L Bhatt
2
,
Carol A Connell
3
Affiliations
1
Mayo Clinic, Rochester, MN ytterberg.steven@mayo.edu.
2
Brigham and Women's Hospital, Boston, MA.
3
Pfizer, Groton, CT.
PMID:
35507493
DOI:
10.1056/NEJMc2202778
No abstract available
Publication types
Letter
Comment
MeSH terms
Arthritis, Rheumatoid* / complications
Arthritis, Rheumatoid* / drug therapy
Humans
Neoplasms*
Piperidines / adverse effects
Pyrimidines / adverse effects
Substances
Piperidines
Pyrimidines
tofacitinib